Fig. 6

Composite endpoint^a in the 183 days before and after erenumab initiation. ^aOutpatient visit with a diagnosis of migraine and an associated acute medication claim, hospital admission or emergency room visit with a primary diagnosis for migraine. Any events occurred ≤3 days apart were counted only once. McNemar test for binary endpoint and Negative binomial with repeated measure for count data were used. ^bNumber of events are plotted as relative risk and 95% confidence intervals